Key facts
- Nordic Bioproducts Group’s last known valuation is $63.9M (Aug 2022).
- It has raised $38.7M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Aalto University, CMPC Ventures, Oji Holdings, Taaleri Bioindustry.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nordic Bioproducts Group
- ·The full record, as it builds
Funding rounds
No funding rounds for Nordic Bioproducts Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nordic Bioproducts Group
Developer of intelligent biotechnologies designed to redesign cellulose into high-value bioproducts. The company's biotechnologies help industries to combat the effects of global warming with innovative bioproducts and bioproduction technologies that work with food, pharma, plastics, and textiles, and create a healthy, carbon-neutral, and sustainable future for the planet and profit for the businesses, enabling industries to create bioproducts with positive economic, environmental, and social impact.
- Sector
- Materials and Resources
- HQ
- Espoo, Finland
- Founded
- 2019
- Employees
- 30
- Website
- nordicbioproducts.fi/
- Ownership
- Privately Held (backing)
Nordic Bioproducts Group doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nordic Bioproducts Group shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nordic Bioproducts Group in its N-PORT filings yet. We sweep new filings monthly.